Want to see IN:WOCKPHARMA full AI Analyst Report?
Wockhardt Limited (WOCKPHARMA) Price & Analysis
WOCKPHARMA Stock Chart & Stats
- Day’s Range
- INR 1,868.60 - INR 1,929.90
- 52-Week Range
- INR 1,086.80 - INR 2,420.00
- Previous Close
- INR 1,921.45
- Volume
- 236.67K
- Average Volume (3M)
- 59.98K
- Market Cap
- INR 308.09B
- Enterprise Value
- INR 210.41B
- Total Cash (Recent Filing)
- INR 6.80B
- Total Debt (Recent Filing)
- INR 0
- Price to Earnings (P/E)
- 75.6
- Beta
- 1.32
- Next Earnings
- Nov 02, 2026
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Recovery
The return to steady revenue growth indicates improving demand and commercial execution across Wockhardt’s pharmaceutical portfolio. Continued top-line expansion can support operating leverage, strengthen reinvestment capacity, and provide a more durable base for earnings recovery over the next several quarters.
Return To Profitability
Positive net income marks a meaningful recovery from prior losses and demonstrates that the business can again convert its operations into accounting earnings. If maintained, profitability should improve internal funding capacity and reinforce the company’s ability to invest in products, capabilities, and market access.
Balance-Sheet Cushion
Stable debt alongside a larger equity base improves financial cushioning and reduces the relative burden of leverage on the business. This gives Wockhardt greater resilience while it rebuilds profitability, supporting continued investment and providing more flexibility to manage operating volatility.
Bears Say
Prolonged Earnings Volatility
Several years of losses show that the recent recovery has not yet established a consistently profitable operating model. This history raises the risk that earnings could weaken again if business conditions deteriorate, making long-term performance less predictable and limiting confidence in sustained compounding.
Volatile Operating Profitability
Large swings in EBIT indicate that margins have not yet demonstrated durable stability across reporting periods. Such variability can make earnings sensitive to product mix and operating conditions, complicate planning, and reduce the reliability of profits available for reinvestment or debt servicing.
Uneven Cash Conversion
Modest and inconsistent free cash flow indicates that reported earnings do not always translate into cash available for shareholders or reinvestment. Persistently uneven conversion can constrain funding flexibility, increase reliance on balance-sheet resources, and make the recovery less durable than net income alone suggests.
Wockhardt Limited News
WOCKPHARMA FAQ
What was Wockhardt Limited’s price range in the past 12 months?
What is Wockhardt Limited’s market cap?
When is Wockhardt Limited’s upcoming earnings report date?
How were Wockhardt Limited’s earnings last quarter?
Is Wockhardt Limited overvalued?
Does Wockhardt Limited pay dividends?
What is Wockhardt Limited’s EPS estimate?
How many shares outstanding does Wockhardt Limited have?
What happened to Wockhardt Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Wockhardt Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Wockhardt Limited
Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an antibiotic for gram-negative infections; MIQNAF nafithromycin, which targets azithromycin-resistant community respiratory pathogens; and ODRATE, a once-daily combination of ertapenem and zidebactam for resistant gram-negative infections through outpatient parenteral antimicrobial therapy. In addition, it develops and commercializes insulin analogs, glucagon-like peptide-1 agonists, and novel combination drug products; Biovac-B, a recombinant hepatitis-B vaccine; Wepox, a recombinant human erythropoietin; Wosulin, a recombinant human insulin; and Glaritus, a recombinant insulin glargine. Further, the company offers delivery devices for insulin, including Dispopen disposable pen and Mypen reusable pen. Wockhardt Limited was founded in 1967 and is headquartered in Mumbai, India.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Murtaza Khorakiwala
- Employees
- 2,564
- Website
- www.wockhardt.com
- Address
- Wockhardt Towers, Mumbai, MH, 400051, IN
Wockhardt Limited (WOCKPHARMA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 6 | 9 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 5 | 0 | 7 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| IN:AJANTPHARMAjanta Pharma Limited | ||
| IN:ALKEMAlkem Laboratories Ltd. | ||
| IN:EMCUREEmcure Pharmaceuticals Limited | ||
| IN:GLENMARKGlenmark Pharmaceuticals Limited | ||
| IN:IPCALABIPCA Laboratories Limited |








